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Background: Exercise capacity is impaired in pulmonary arterial hypertension (PAH). We hypothesized that
cardiovascular reserve abnormalities would be associated with impaired hemodynamic response to
pharmacological stress and worse outcome in PAH.
Methods: Eighteen PAH patients (p) group 1 NYHA class II/III and ten controls underwent simultaneous right
cardiac catheterization and intravascular ultrasound at rest and during low dose-dobutamine (10 mcg/kg/min) with
trendelenburg (DST). We estimated cardiac output (CO), pulmonary vascular resistance (PVR) and capacitance (PC),
and PA elastic modulus (EM). We concomitantly measured tricuspid annular plane systolic excursion (TAPSE), RV
myocardial peak systolic velocity (Sm) and isovolumic myocardial acceleration (IVA) in PAH patients. Based on the
rounded mean + 2 SD of the increase in mPAP in our healthy control group during DST (2.8 + 1.8 mm Hg), PAH p
were divided into two groups according to mean PA pressure (mPAP) response during DST, 1: ΔmPAP > 5 mm Hg
and 2: ΔmPAP ≤ 5 mm Hg. Cardiovascular reserve was estimated as the change (delta, Δ) during DST compared
with rest, including ΔmPAP with respect to ΔCO (ΔmPAP/ΔCO). All patients were prospectively followed up for
2 years.
Results: PAH p showed significant lower heart rate and CO increase than controls during DST, with a
significant mPAP and pulse PAP increase and higher ΔmPAP/ΔCO (p < 0.05). Neither hemodynamic, IVUS and
echocardiographic data were different between both PAH groups at rest. In group 1, DST caused a higher ΔEM,
ΔmPAP/ΔCO, ΔPVR, and ΔTAPSE than group 2, with a lower IVA increase and a negative ΔSV (p < 0.05). TAPSE
correlated with mPAP and RVP (p < 0.05) and, IVA and Sm correlated with CO (p < 0.05). ΔEM correlated with ΔmPAP
and ΔIVA with ΔCO (p < 0.05). There were two deaths/pulmonary transplantations in group 1 and one death in group
2 during the follow-up (p > 0.05).
Conclusions: Pulmonary vascular reserve and RV systolic reserve are significantly impaired in patients with PAH. The
lower recruitable cardiovascular reserve is significantly related to a worse hemodynamic response to DST and it could
be associated with a poor clinical outcome.
Keywords: Pulmonary hypertension, Dobutamine, Cardiovascular reserve, IVUS, Echocardiography* Correspondence: jgrig@fmed.edu.uy
†Equal contributors
3Pathophysiology Department, School of Medicine, Hospital de Clínicas,
Universidad de la República, Avda Italia 2870, PC 11600 Montevideo,
Uruguay
Full list of author information is available at the end of the article
© 2014 Domingo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Domingo et al. BMC Pulmonary Medicine 2014, 14:69 Page 2 of 10
http://www.biomedcentral.com/1471-2466/14/69Background
Normal pulmonary circulation is characterized by low
pressure and low vascular resistance. Mean pulmonary
arterial pressure (mPAP) at rest is virtually independent
of age and rarely exceeds 20 mm Hg (14 ± 3.3 mm Hg).
In healthy individuals, passive distension of compliant
pulmonary circulation and active flow-mediated vaso-
dilation allows the pulmonary vasculature to accommo-
date increased cardiac output (CO) with only a modest
increase in mPAP and a fall in pulmonary vascular re-
sistance (PVR) [1-3]. Invasive hemodynamic monitoring
during incremental exercise testing is technically difficult
to perform and not routinely incorporated into clinical
exercise testing. A recent systematic review has reported
an age-dependent increase of mPAP that may exceed
30 mm Hg particularly in subjects aged ≥ 50 years, mak-
ing it difficult to clearly define normal mPAP values during
exercise [2]. In idiopathic pulmonary arterial hypertension
(PAH), exercise capacity is markedly impaired due to an
inefficient lung gas exchange (ventilation/perfusion mis-
matching with an increased dead space ventilation) and
the inability of the heart to adequately increase pulmonary
blood flow during exercise [4]. The pathophysiological
mechanisms leading to an abnormal exercise response
include an intrinsic abnormality in the pulmonary vascula-
ture due to the pulmonary arterial (PA) wall remodeling
[5] and a reduction in stroke volume and right ventricular
(RV) ejection fraction [6]. Laskey et al. have demonstrated
that both steady and pulsatile components of the PA vas-
cular hydraulic load have considerable impact on exer-
cise response in primary pulmonary hypertension [7].
It has already been reported that improvement in ex-
ercise tolerance in PAH patients with chronic therapy
is independently related to improvements in pulmonary
hemodynamics measured in exercise but not in resting
conditions, suggesting an improve in the vascular reserve
[8]. Lau et al. did not observe any significant beneficial
effects of bosentan on arterial stiffness following 6-months
of therapy [9].
Exercise echo-Doppler is being used with increased
frequency in the assessment of patients with known or
suspected pulmonary vascular disease, focusing on the
change in Doppler-estimated PAP with exercise. How-
ever, there are surprisingly few data about RV function
at exercise, especially considering that the impaired RV
functional reserve could get involved in the mechanism
of exercise limitation in PAH and other forms of pul-
monary vascular diseases [10]. Recently, Blumberg et al.
showed that the ability to increase the cardiac index dur-
ing exercise is an important determinant of exercise cap-
acity and it is linked to survival in patients with PH [11].
We hypothesized that abnormalities in cardiovascular
reserve would be associated with impaired hemodynamic
response to pharmacological stress and worse outcomein PAH. Therefore, the first aim of the present study was to
perform RV systolic function assessment (echocardiography)
and hemodynamic monitoring (right heart catheterization)
including local elastic properties of proximal PA wall
(intravascular ultrasound, IVUS) during dobutamine stress
in patients with PAH. The second aim was to evaluate the
association between the cardiovascular reserve and the out-
come during two years follow-up.
Methods
Ethics statement
The investigation conforms with the principles outlined
in the Declaration of Helsinki. The study protocol was
approved by the Institutional Ethics Committee of the
Hospital Universitari Vall d’Hebron (Barcelona), and all
patients gave written informed consent.
Study population
Eighteen consecutive patients with PAH (Dana Point
group 1) under specific drug therapy who underwent a
follow-up cardiac catheterization at our institution were
included in the study from January 2007 to September
2009. The patients were in NYHA function class II-III,
with no clinical and pharmacological changes in the last
4–6 months. Exclusion criteria were: refusal to partici-
pate in the study or being in NYHA function class IV.
The diagnosis of PAH was made according to the standard
algorithm including a right heart catheterization [12].
Causes of PAH were idiopathic PH (n = 12), PH related to
connective tissue disease (n = 3), surgically corrected con-
genital heart disease (n = 1), PH associated with human
immunodeficiency virus (n = 1) and porto-pulmonary
hypertension (n = 1). Chronic medication included oral
anticoagulants, diuretics on demand, bosentan, sildenafil,
inhaled iloprost and epoprostenol, as well as combination
therapies on clinical judgement. Age and sex matched
control subjects were recruited initially referred for car-
diac catheterization due to clinically suspected PAH, with-
out any other heart or lung disease. They underwent the
same invasive study protocol after documentation of nor-
mal pulmonary arterial hemodynamics.
All subjects underwent a routine right heart catheterization
and simultaneous inferior lobe medium-sized elastic pul-
monary artery IVUS in the supine position and breathing
room air. A transthoracic echocardiographic study was
performed concomitantly in PAH patients by a single
experienced examiner. All variables were obtained at rest
and during dobutamine stress test with simultaneous
Trendelenburg (DST). DST consisted of low-dose dobuta-
mine infusion (10 mcg/kg/min) in order to increase myo-
cardial contractility and heart rate, and 30° Trendelenburg
position in order to increase venous return (preload),
both during 10 minutes, unless symptoms (shortness of
breath, chest pain, systemic hypertension with systolic
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than sinus tachycardia) were observed. These three vari-
ables (venous return or preload, heart rate and myocardial
contractility) are the leading factors responsible for the in-
crease in CO during exercise [1]. We choose a low-dose
dobutamine stress test with simultaneous Trendelenburg
as an easy maneuver to induce a purely passive increase of
pulmonary flow and a change in cardiac contractility, in
order to assess the cardiovascular reserve [2].
PAH patients were prospectively followed up for 2 years.
Physicians who carried out the clinical follow-up were
blinded to the hemodynamic, IVUS and echocardio-
graphic results.
Hemodynamic and IVUS studies
A 7 F Swan-Ganz catheter (Edwards Lifesciences, USA)
was inserted into a brachial vein and a 5 F end-hole
catheter was inserted into the right radial artery to
monitor systemic arterial pressure. Both catheters were
connected to fluid-filled transducers, which were posi-
tioned at the anterior axillary line level and zeroed at at-
mospheric pressure. Right atrial, PAP and pulmonary
capillary wedge pressures were all measured at end-
expiration. CO was calculated using the Fick method. In
patients with tricuspid regurgitation and low CO, such
as those with PAH, the thermodilution method has not
been reported to be more accurate than the Fick method
[13], however in this series no patient presented tri-
cuspid regurgitation greater than mild in the echocar-
diographic assessment nor at rest neither at peak stress.
PVR was calculated as: (mPAP-pulmonary capillary wedge
pressure)/CO and total pulmonary resistance (TPR) as:
mPAP/CO. Pulmonary vascular capacitance (PC) was
estimated by the stroke volume/pulse pressure ratio (SV/
pPAP) [14]. The changes in mPAP were normalized by
the changes in CO (ΔmPAP/ΔCO) during pharmaco-
logical stress, in order to interpret exercise-induced in-
creases in mPAP relative to increases in blood flow [15].
IVUS examination was performed with an Eagle Eye
Gold catheter 20 MHz, 3.5 F (Volcano Corporation,
USA) with an axial resolution of 200 μm and an auto-
matic pullback of 0.5 mm/s. The images were obtained
from a segmental PA of the inferior lobe (elastic PA be-
tween 2–3 mm) [16-18] and stored in digital form. Both
diastolic and systolic cross-sectional areas of the stud-
ied segment were analyzed off-line by two observers
unaware of clinical and hemodynamic findings. We
estimated IVUS pulsatility (IVUSp) as: (systolic-diastolic
lumen area)/diastolic lumen area × 100. The physiological
adaptation of the vessel wall to stress was estimated by
the elastic modulus (EM) or pressure/elastic strain
index (pulse pressure/IVUSp), an expression of the in-
trinsic PA wall viscoelastic properties and buffering
function. Intra- and inter-observer validation of IVUSmeasurements in our laboratory has been previously
published [16,18].
Transthoracic echocardiography-Doppler study
Baseline and stress echocardiography was performed
using commercially available equipment (Vivid 7 digital
GE Medical System) with a standard 2D broad-band
phased array M4S transducer and tissue Doppler im-
aging software. The transducer was maximally aligned to
optimize endocardial visualization and spectral displays
of Doppler profiles. Real-time 2-D and colour Doppler
myocardial imaging were performed in the apical 4-
chamber view as well as the parasternal short-axis and
subcostal views. The predominantly longitudinal con-
tractile pattern of the RV can be exploited to assess RV
systolic function [19]. We estimated the global RV sys-
tolic longitudinal function by the tricuspid annular plane
systolic excursion (TAPSE) measured from the systolic
displacement of the RV free wall-tricuspid annular plane
junction in the apical 4-chamber view M-mode record-
ings. Myocardial peak velocity during ejection phase (Sm)
was assessed by tissue Doppler imaging in the basal seg-
ment of the RV free wall using spectral pulsed wave tissue
Doppler recorded at a sweep speed of 100–150 mm/s.
Myocardial acceleration during isovolumic contraction
(IVA) was calculated as the maximal isovolumetric myo-
cardial velocity divided by the time to peak systolic vel-
ocity, as previously described by Vogel et al. [20]. This
method seems to be less load-dependent compared to the
other two indices. Patients were required to hold their
breath and images were obtained immediately after expir-
ation for better image quality. All patients were in sinus
rhythm, and an average of 3 to 5 measurements from con-
secutive cardiac cycles were employed for data analysis.
All examinations were recorded digitally for subsequent
blinded off-line analysis on EchoPAC GE Medical System.
The estimation of intraobserver and interobserver repro-
ducibility was analyzed.
Cardiovascular reserve analysis
Cardiovascular reserve was expressed as the change (in-
crease or decrease) in heart rate (ΔHR, chronotropic re-
serve), RV systolic function (ΔIVA, systolic reserve) and
pulmonary vascular function (ΔEM and ΔPVR, vascular
reserve) during DST when compared with rest [21].
Statistical analysis
Continuous variables are expressed as mean ± SEM. Based
on the rounded mean + 2SD of the increase in mPAP in our
healthy control group during DST (2.8 + 1.8 mm Hg), PAH
patients were divided, prior to analysis, into two groups
according to their hemodynamic response to pharmaco-
logical stress: group 1 included those patients whose
mPAP during stress increased > 5 mm Hg with respect to
Table 2 Hemodynamic and IVUS data of control subjects
and patients with PAH at rest and during stress
maneuver
PAH patients (n = 18) Control patients (n = 10)
Rest Stress Rest Stress
CO, L/min 4.0 ± 0.3 5.6 ± 0.4§ 4.7 ± 0.1 8.6 ± 0.2*§
HR, bpm 76 ± 3 104 ± 3.6§ 73 ± 1.3 114 ± 1.5*§
SV, mL 55 ± 5.1 55 ± 2.2 64.5 ± 1.4 78 ± 2*§
mPAP, mm Hg 52 ± 4 61 ± 5§ 15 ± 2* 18 ± 1.2*§
pPAP, mm Hg 49 ± 21 65 ± 6§ 11 ± 3* 15 ± 1.1*§
PCWP, mm Hg 10.3 ± 1.0 7.3 ± 0.9 8.8 ± 0.6 11 ± 0.7
RAP, mm Hg 7.4 ± 0.9 7.7 ± 0.9 5.0 ± 1.2 6.5 ± 1.1
PVR, Wood units 12 ± 1.7 11.4 ± 1.9 3 ± 0.3* 1.9 ± 0.17*§
PC, mL/mm Hg 1.5 ± 0.26 1.1 ± 0.2§ 6.2 ± 0.4* 5.5 ± 0.6*
TPR, Wood units 14.8 ± 1.9 13.1 ± 2.0§ 3.3 ± 0.25 2.1 ± 0.16*§
IVUSp, % 33 ± 4.8 27 ± 4 52 ± 2.5* 85 ± 3.4*§
EM, mm Hg 184 ± 25 275 ± 36§ 21 ± 1.9* 18 ± 1.7*§
*p < 0.05 between both groups in the same condition; §p < 0.05 between both
conditions in the same group.
CO: cardiac output; PC: pulmonary capacitance index; EM: elastic modulus; HR:
heart rate; IVUSp: pulmonary arterial pulsatility; mPAP and pPAP: mean and
pulse arterial pulmonary pressures; PCWP: pulmonary capillary wedge
pressure; PVR: pulmonary vascular resistance; RAP: right atrial pressure; SV:
stroke volume; TPR: total pulmonary resistance.
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with a mPAP increase ≤ 5 mm Hg. Independent sample
t-tests were used to compare differences between the
control and PAH groups; and paired t-tests were used
to compare the effects of stress maneuver within each
group. Chi-squared was used for comparing proportions
of patients. Intergroup variation was analyzed using one-
way ANOVA.
The association between hemodynamic response (ΔCO,
ΔmPAP) and cardiovascular reserve (ΔIVA, ΔEM, ΔPVR)
were explored using linear regression analysis (Pearson
coefficient). A two-sided P value < 0.05 was regarded as
significant. Data analysis were carried out using SPSS 17.0
for Windows 7 software.
Results
Comparison between PAH patients and control subjects
at rest and during pharmacological and positional stress
The age and gender of PAH subjects and control subjects
were well matched (Table 1). Table 2 shows hemodynamic
and IVUS data of both, control subjects and PAH patients
at rest and during DST. PAH patients showed higher
mPAP, pPAP, PVR, TPR and EM and lower PC and IVUSp
than control subjects (P < 0.05). There were no significant
difference in heart rate, SV, CO, right atrial pressure and
pulmonary capillary wedge pressure between both groups.
During DST healthy controls showed an increase of
CO, SV and heart rate (P < 0.05) with a significant reduc-
tion in PVR and TPR, and improvement of IVUSp and
EM (P < 0.05) (Table 2). These changes led to an attenu-
ated increase in mPAP and pPAP. Mean systolic aortic
pressure was 127 mm Hg at rest and 165 mm Hg during
stress (P < 0.05). None of control subjects exceeded 20 mm
Hg of mPAP at rest and 30 mm Hg during stress.
All PAH patients tolerated the stress protocol. No do-
butamine infusion had to be interrupted at the doses
employed for this study and no complications were
observed. No patients included in this study presented
greater than mild tricuspid regurgitation (≤ grade 2/4),
and there were no relevant changes in its severity during
the complete protocol. Only six of 18 PAH patientsTable 1 Demographic, anthropometric and clinical data of co
All PAH PAH 1
(n = 18) (ΔmPAP > 5)
Demographic
Age, years 51 ± 3.7 47 ± 5
Gender, M/F 7/11 3/6
BSA, m2 1.76 ± 0.05 1.73 ± 0.
Functional status
NYHA class II/III 10/8 5/4
6MWD, m 390 ± 26 396 ± 4
BSA: body surface area; 6MWD: six minute walking distance.increased SV, and the heart rate increase was significantly
lower than control subjects (29 ± 3.8 vs. 41 ± 2 bpm,
P = 0.034), therefore the CO increment was mainly
dependent on heart rate increase. mPAP, pPAP and
EM increased significantly and PC significantly decreased
during stress (Table 2). However, they showed an in-
crease in all the RV systolic function indexes during stress
(TAPSE 16.8 ± 1.3 vs. 20.2 ± 1.1 mm, P = 0.02; Sm 12.0 ±
0.5 vs. 14.7 ± 0.8 cm ⋅ s−1, P = 0.003; IVA 3.8 ± 0.3 vs. 7.8 ±
0.9 m ⋅ s−2, P = 0.0003). The CO increase was less marked
than in healthy controls (P < 0.05), and consequently,
ΔmPAP/ΔCO was higher (9.6 ± 3.1 vs. 0.7 ± 0.1 mm Hg/
L/min, P = 0.046) in PAH patients than in controls
(Figure 1). High quality RV velocity curves were obtained
both at rest and stress in 16 out of 18 patients.ntrol subjects and patients with PAH
PAH 2 Controls
(n = 9) (ΔmPAP≤ 5) (n = 9) (n = 10)
55 ± 5 51 ± 1.8
4/5 4/6
06 1.80 ± 0.05 1.80 ± 0.04
5/4
1 383 ± 33
Table 3 Hemodynamic, IVUS and echocardiographic data
at rest and during stress maneuver of both PAH groups
PAH 1 PAH 2
ΔmPAP > 5 (n = 9) ΔmPAP≤ 5 (n = 9)
Rest Stress Rest Stress
CO, L/min 3.8 ± 0.5 5.0 ± 0.7§ 4.2 ± 0.4 6.1 ± 0.5§
HR, bpm 76 ± 4 104 ± 5.3§ 75 ± 4.6 105 ± 5.1§
SV, mL 54 ± 9 50 ± 9§ 56 ± 6 60 ± 5
mPAP, mm Hg 54 ± 6.7 71 ± 7.2§ 50 ± 4.7 51 ± 4.6*
pPAP, mm Hg 52 ± 6.7 76 ± 9.2§ 45 ± 7.6 53 ± 6.4*
PCWP, mm Hg 10.6 ± 1.1 9.4 ± 1.1 10.3 ± 1.9 6.0 ± 1.3
RAP, mm Hg 7.9 ± 1.0 8.4 ± 0.8 6.9 ± 1.6 7.1 ± 1.2
PVR, Wood units 13.7 ± 2.8 14.9 ± 3.1 10.3 ± 1.7 7.9 ± 1.3*§
PC, mL/mm Hg 1.38 ± 0.4 0.9 ± 0.4§ 1.6 ± 0.38 1.3 ± 0.2
TPR, Wood units 16.6 ± 3.1 17.0 ± 3.1 13.1 ± 2.2 9.2 ± 1.8*§
IVUSp, % 29 ± 5.7 26 ± 6.6 38 ± 7.8 28 ± 4.8
EM, mm Hg 211 ± 32 362 ± 55§ 158 ± 39 187 ± 23*
TAPSE, mm 16.4 ± 1.9 20.8 ± 1.9§ 20.3 ± 1.4 19.6 ± 1.1
Sm, cm ⋅ s−1 12.1 ± 0.64 15.3 ± 1.2§ 12.8 ± 1.0 13.3 ± 1.0
IVA, m ⋅ s−2 3.3 ± 0.35 5.9 ± 0.7§ 4.3 ± 0.5 9.9 ± 1.5*§
*p < 0.05 between both groups in the same condition; §p < 0.05 between both
conditions in the same group.
CO: cardiac output; PC: pulmonary capacitance index; EM: elastic modulus; HR:
heart rate; IVA: myocardial isovolumic acceleration; IVUSp: pulmonary arterial
pulsatility; PCWP: pulmonary capillary wedge pressure; mPAP and pPAP: mean
and pulse arterial pulmonary pressures; PVR: pulmonary vascular resistance;
Sm: myocardial peak systolic velocity; RAP: right atrial pressure; SV: stroke
volume; TAPSE: tricuspid annular plane systolic excursion; TPR: total
pulmonary resistance.
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data in PAH patients according to ΔmPAP during
pharmacological and positional stress
Nine patients increased mPAP > 5 mm Hg (group 1) and
nine patients changed mPAP ≤ 5 mm Hg (group 2) during
stress. Etiology of group 1 was 5 IPAH, 2 scleroderma-
associated PAH, 1 congenital cardiac shunt and 1 HIV PH.
Etiology of group 2 was 7 IPAH, 1 scleroderma-associated
PAH and 1 porto-pulmonary hypertension. Neither demo-
graphic nor clinical differences between PAH group 1 and
PAH group 2 were found (Table 1). Accordingly, neither
hemodynamic nor IVUS data showed differences between
both PAH patients groups at rest (Table 3).
Both PAH groups increased CO during DST (P < 0.05),
although without significant differences between them
(1.14 ± 0.3 vs. 1.9 ± 0.3 L/min, NS). Only PAH group 1
showed a significant increase in mPAP, decreasing PC
and increasing EM significantly, with no change in PVR
and TPR. PAH group 2 decreased PVR and TPR without
significant change in PC, IVUSp and EM (Table 3). PVR
decreased in 2/9 patients in group 1 and in 8/9 in group
2 (P < 0.05). PC decreased in 9/9 patients in group 1 and
in only 4/9 in group 2 (P = 0.08). Starting from a similar
EM at rest, the EM of PAH group 1 was significantly
higher than PAH group 2 (362 ± 55 vs. 187 ± 23 mm Hg,
P < 0.05, Table 3) during DST.
RV systolic function indexes were similar between both
PAH patients groups at rest. DST unmasked a significant
lower increase of IVA of PAH group 1 with respect to
PAH group 2 (5.9 ± 0.7 vs. 9.9 ± 1.5 m ⋅ s−2) (Table 3).
Concomitantly, SV decreased (P < 0.05) in PAH group 1
during stress.Figure 1 Relationship between mean pulmonary artery
pressure (mPAP) and cardiac output at rest and during
pharmacological and positional stress. (Filled circle: PAH patients;
filled square: control patients).Cardiovascular reserve responses during pharmacological
and positional stress
Control subjects showed a higher chronotropic (Δheart
rate) and systolic reserve (measured by ΔSV) than PAH pa-
tients (P < 0.05). The negative change in ΔEM and ΔPVR
during stress revealed an increased vascular reserve associ-
ated with a low ΔmPAP/ΔCO ratio (Table 4).
Considering all PAH patients, resting EM, but nei-
ther PVR nor PC, was correlated with ΔmPAP (r = 0.49,
P < 0.005) and ΔCO (r = −0.72, P < 0.0001).
Global cardiovascular reserve was impaired in PAH
group 1, showing the higher increase in ΔEM, higher
ΔmPAP/ΔCO ratio, with a negative change in ΔSV and a
positive change in ΔPVR and ΔTPR. By contrast PAH
group 2, showed some extent of cardiovascular reserve,
illustrated by the changes of ΔEM, ΔPVR, ΔmPAP/ΔCO
ratio and ΔSV with respect to control patients (Table 4).
In PAH patients, in whom RV systolic function was ana-
lyzed, TAPSE correlated with mPAP and PVR (r = 0.58
and r = 0.51, respectively; P < 0.05), whereas, IVA and Sm
were correlated with CO (r = 0.32 and r = 0.5, respectively;
P < 0.05) (Table 5). Finally, ΔEM only correlated with
ΔmPAP (r = 0.56, P < 0.05) and ΔIVA was correlated with
ΔCO (r = 0.5, P < 0.05) (Figure 2).
Table 4 Cardiovascular reserve response of control subjects and both PAH groups
PAH 1 PAH 2 Control
ΔmPAP > 5 (n = 9) ΔmPAP≤ 5 (n = 9) (n = 10)
ΔCO, L/min 1.1 ± 0.3 1.9 ± 0.3 4.2 ± 0.3*§
ΔHR, bpm 30 ± 5.2 28 ± 5.8 41 ± 2.1*§
ΔSV, mL −4.1 ± 1.3 3.2 ± 2.8† 13.2 ± 2.8*§
ΔmPAP, mm Hg 17 ± 3.2 0.8 ± 0.9† 2.8 ± 0.3*
ΔpPAP, mm Hg 25 ± 4.8 7.2 ± 3.7† 4.0 ± 0.6*
ΔPVR, Wood units 1.2 ± 0.6 −2.4 ± 0.6† −1.0 ± 0.2*§
ΔPC, mL/mm Hg 0.46 ± 0.11 0.3 ± 0.2 −0.7 ± 0.4
ΔTPR, Wood units 0.5 ± 0.48 −3.9 ± 0.7† −1.2 ± 0.12*§
ΔIVUSp, % 2.8 ± 2.2 9.4 ± 6.7 32.5 ± 3.2*§
ΔEM, mm Hg 151 ± 29 30 ± 36† −3 ± 1.2*
ΔmPAP/ΔCO, mm Hg/L/min 19.5 ± 3.9 0.3 ± 1.3† 0.7 ± 0.07*
ΔTAPSE, mm 4.4 ± 0.9 0.09 ± 1.1†
ΔSm, cm ⋅ s−1 3.4 ± 1.2 1.8 ± 0.8
ΔIVA, m ⋅ s−2 3.2 ± 0.9 4.9 ± 1.4
†p < 0.05, PAH 1 vs. PAH 2; *p < 0.05, Control vs. PAH 1; §p < 0.05, Control vs. PAH 2.
CO: cardiac output; PC: pulmonary capacitance index; EM: elastic modulus; HR: heart rate; IVA: myocardial isovolumic acceleration; IVUSp: pulmonary arterial
pulsatility; mPAP and pPAP: mean and pulse arterial pulmonary pressures; PVR: pulmonary vascular resistance; Sm: myocardial peak systolic velocity; SV: stroke
volume; TAPSE: tricuspid annular plane systolic excursion; TPR: total pulmonary resistance. Δ = delta.
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IVA measurements were 4.4% and 3.4% respectively.
In the 2-year clinical follow-up there were two deaths/
pulmonary transplantations in PAH group 1 and one death
in PAH group 2 (P > 0.05).
Discussion
This is the first study evaluating the cardiovascular re-
serve in PAH patients. We show that the hemodynamic
response to pharmacological stress with low-dose dobu-
tamine plus 30° Trendelenburg position is significantly
impaired in patients with PAH, and this impairment is
associated with a low RV systolic reserve and pulmon-
ary vascular reserve. The lower cardiovascular reserve
is significantly related to a worse hemodynamic adap-
tation to DST and it could be associated with a poor
clinical outcome.Table 5 Correlations between right ventricular systolic
tissue Doppler variables and hemodynamics during both
conditions (rest and stress maneuver)
TAPSE Sm IVA
r p Value r p Value r p Value
mPAP 0.58 0.0004 0.24 0.09 0.17 0.72
PVR 0.51 0.002 0.26 0.08 0.19 0.16
CO 0.11 0.244 0.32 0.04 0.5 0.0026
CO: cardiac output; IVA: myocardial isovolumic acceleration; mPAP: mean
and pulse arterial; PVR: pulmonary vascular resistance; Sm: myocardial
peak systolic velocity; TAPSE: tricuspid annular plane systolic excursion.
(r: Pearson coefficient).Pharmacological and positional stress
Cardiovascular reserve is emerging as a strong predictor
of outcome in different cardiovascular diseases [21]. From
a physiological point of view, cardiovascular reserve is a
measure of cardiovascular response to exercise or pharma-
cological stresses (dobutamine infusion between 4 and 10
mcg/kg/min) [22]. Although exercise stress is the gold
standard to evaluate of the pulmonary vascular pressure-
flow relationships, exercise hemodynamics in PAH pa-
tients have been poorly studied, and factors that may have
an impact on PAP response to exercise, such as exercise
method, exercise intensity, position and age, have not been
accounted for. The stress maneuver used in our study pro-
vided by low-dose dobutamine plus 30° Trendelenburg
position works by a purely passive increasing in CO with-
out directly influence on the PA wall viscoelastic properties.
In experimental pulmonary hypertension, dobutamine infu-
sion at a rate of 10 mcg/kg/min has no flow-independent
effects on the normal or acutely hypertensive circulation.
Higher doses may have a constricting or dilating effect de-
pending on the pre-existing vascular tone [22-24].
Taking into account the extent of heart rate and CO
reached by healthy subjects during pharmacological
and positional stress, we achieved a cardiovascular stress
level similar to a slight/moderate exercise (heart rate 100–
110 bpm and cardiac output 10–14 L/min) [2]. According
to the data reviewed by Kovacs et al., mPAP values during
slight exercise in healthy subjects were 29.4 ± 8.4 mm Hg,
20.0 ± 4.7 mm Hg and 18.2 ± 5.1 mm Hg in subjects aged ≥
50 years, 30–50 years and less than 30 years, respectively
Figure 2 Relationship between hemodynamic response and cardiovascular reserve. A. Correlation between delta elastic modulus (ΔEM)
and delta mean pulmonary artery pressure (ΔmPAP); B. correlation between ΔEM and delta cardiac output (ΔCO); C. correlation between delta
myocardial isovolumic acceleration (ΔIVA) and ΔmPAP; D. correlation between ΔIVA and ΔCO in PAH patients. (delta = value during dobutamine
stress test and Trendelenburg minus value at rest).
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40–60 years; 50% ≤ 50 years) and showed a similar mPAP
(18 ± 4 mm Hg) with a similar CO increase (doubled) dur-
ing DST.
Cardiovascular reserve in PAH versus control patients
In the control group, the marked increase in CO during
DST did not cause any significant change in mPAP and
determined a low ΔmPAP/ΔCO ratio (0.7 ± 0.2 mm Hg/
L/min). This value corresponds well to the cohort of
Kovacs et al. which reported a ΔmPAP/ΔCO ~1.06 mm
Hg/L/min [25].
The modest increment in mPAP relative to CO during
pharmacological stress is attributable to passive recruit-
ment and distension of a normally compliant pulmonary
circulation with active flow-mediated vasodilation, de-
creasing PVR and TPR [15]. Studies into the regulationof pulmonary vascular tone during exercise demonstrate
the importance of nitric oxide in the exercise-induced
pulmonary vasodilatation, which is mediated in part via
blunting of the vasoconstrictor influence of endothelin
[26]. Concomitantly, pharmacological stress produced an
increase in arterial pulsatility (estimated by IVUSp), and
a decrease of EM, expressing a preserved buffering func-
tion. It is accepted that the arterial wall buffering function
is determined not only by arterial elastic properties, but also
by the viscous properties of the wall. The characterization
of wall buffering function has been estimated by means of
the ratio between viscous index/elastic index [27]. Consid-
ering our stress condition as a mainly passive condition
(with no significant change in viscous index), a decreased
EM with a negative ΔEM, would be associated with a pre-
served buffering function and buffering function reserve,
respectively. The negative change in ΔPVR with a low
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dilator reserve. In clinical practice, ventricular systolic
reserve is usually defined by a change in ejection frac-
tion or SV during exercise or dobutamine infusion. Even
though we did not assess RV function indices in the con-
trol group, the observed CO increase was composed by a
56% increase in heart rate (chronotropic reserve) and 20%
(13 mL) increase in SV (systolic reserve).
Although, both controls and PAH patients had similar
heart rate at rest, PAH cohort showed an impaired chron-
otropic response during stress maneuver. This chronotro-
pic incompetence has been previously documented by
Provencher et al. and may reflect the loss of normal
physiological reserve secondary to significant autonomic
nervous system abnormalities and probably as a result of
down-regulation of β-adrenoreceptors [28,29].
Both PAH patient groups had similar resting hemodynamics
and chronotropic reserve. However, the higher increase in
mPAP and pPAP with similar increase of CO during stress
in PAH group 1 with respect to PAH group 2, would be
related to the reduced recruitability and distensibility of
more highly remodeled pulmonary vessels. This illustrates
a lack of physiological adaptation of the PA wall to in-
creased flow in relation with a lower vasodilation reserve
(positive ΔPVR), a higher PA wall remodeling (higher rest-
ing EM) and a concomitantly lower buffering function
(higher ΔEM). By contrast, PAH group 2 preserved some
extent of vascular reserve secondary to a vasodilation
response (negative ΔPVR) and a lower impairment of
buffering function (lower positive ΔEM). This would ex-
plained the significant lower ΔmPAP/ΔCO ratio than
group 1. Accordingly, we have previously reported that
PAH patients with higher IVUSp and lesser EM displayed
an absolute PA vasodilation during acute vasoreactivity
testing [18]. We cannot discard the presence of alter-
ations in the control of pulmonary vascular tone dur-
ing DST, resulting in blunted pulmonary vasodilation.
Since both PAH groups have neither demographic (age,
gender or body surface area) nor clinical differences (func-
tional class, 6 minutes walking distance, etiology of PAH),
we can speculate that PAH group 1 could have higher
endothelial dysfunction with higher imbalance between
vasodilators and vasoconstrictors than group 2, explaining
the significant higher ΔmPAP/ΔCO ratio [26].
In accordance with previous data, resting hemodynamic
measurements are poorly correlated with the response to
pharmacological stress [30]. However, EM at rest was sig-
nificantly correlated with ΔmPAP and ΔCO. Accordingly,
Kubo et al. showed that the percentage of wall thickness
was highly correlated with ΔmPAP during exercise in pa-
tients with severe emphysema [31]. The correlation be-
tween ΔmPAP and ΔEM (Figure 2) suggests that PA wall
remodeling and buffering function impairment would be
associated with the lower vascular reserve.In the context of PAH, evidence of RV dysfunction
and clinical right-sided heart failure at rest have been
shown to be the most important determinants of mor-
bidity and mortality, independently of PAP values. We
used three measures of longitudinal RV shortening in an
effort to characterize simple and reproducible measure-
ments of global RV systolic function [19]. The mean refer-
ence value of TAPSE is 23 mm (16–30), Sm 15 cm ⋅ s−1
(10–19) and IVA 3.7 m ⋅ s−2 (2.2-5.2) [19]. Among them,
TAPSE, a simple and clinically useful tool to estimate RV
function in PAH patients, has been shown to predict sur-
vival in PAH [32]. Preliminary evidence suggests that a de-
crease in TAPSE with exercise was strongly associated
with adverse clinical events in PAH patients within one
year of follow up [33]. However, Giusca et al. suggested
that tricuspid ring motion is only loosely related to RV
systolic function, being highly dependent on afterload and
overall motion of the heart, thus failing to reflect RV lon-
gitudinal function accurately [34]. This may explain why
TAPSE changes are more significantly related to changes
in mPAP and PVR than to true changes in RV systolic
function such as CO. Myocardial deformation parameters
provide a more accurate picture of the contractile status
of the RV free wall [19,34]. IVA appears as a relatively
load-independent estimator of the RV systolic response to
stress, probably reflecting true changes in contractility and
in CO induced by DST. Sm of RV basal free wall is also
better related to CO than TAPSE. However, in this work it
showed a lower ability to identify systolic reserve than
IVA, since there were no Sm differences between both
PAH patients groups either at rest or during stress. Al-
though both PAH patients groups showed similar resting
RV function, PAH group 1 showed a lower RV systolic re-
serve than PAH group 2, estimated by a lower increase
in IVA and a decrease in SV during DST (P < 0.05).
Systolic reserve is dependent on several factors, such as
ventricular contractility, ventricular remodeling and, myo-
cardial interstitial fibrosis. The correlation between ΔCO
and ΔIVA (Figure 2) suggests that RV contractility impair-
ment would explain a lower systolic RV reserve. However,
we cannot discard a stress-induced ischemia and attenu-
ated oxygen supply to the right myocardium during stress
maneuver in more severe PAH patients that could explain
their impaired RV systolic reserve [35,36].
Recently, Blumberg et al. correlated exercise hemodynamics
with peak oxygen uptake and determined their prognostic
significance in PAH patients. Among hemodynamic vari-
ables, only exercise cardiac index and the slope of the pul-
monary pressure/flow relationship were significant prognostic
indicators [11]. Therefore, the exaggerated increase in
mPAP with no concomitant increase in CO (abnormal slope
of the pressure/flow relationship) during DST despite
similar resting hemodynamics, allows speculating a worse
outcome of PAH group 1 with respect to group 2 [11].
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Although care must be taken when comparing hemodynamic
response induced by physical exercise with pharmaco-
logical stress produced by low-dose dobutamine infusion,
the similar response to exercise and to dobutamine infu-
sion at 10 mcg/kg/min in patients with PH following the
Mustard operation is compelling [37].
In addition, our pharmacological stress was a step closer
to real exercise, since increased preload was achieved with
the addition of 30° Trendelenburg. In fact, our stress man-
euver doubled the CO in the control population. The stress
with dobutamine and Trendelenburg works by a purely
passive effect on PVR and PC, mimicking the CO response
to moderate exercise without interfere with PA vascular
tone. Invasive recordings of exercise hemodynamics in
PAH require an intensive protocol, best performed by an
experienced team, and thus it does not belong in the rou-
tine evaluation of PAH patients [8,24]. Our safe stressor
protocol should be viewed as an easier and more reprodu-
cible maneuver than physical exercise in the catheterization
laboratory.
The relative contributions of longitudinal and transverse
shortening to overall RV function have been quantified re-
cently. Although, we only assess RV systolic reserve by
longitudinal shortening indices, Brown et al. showed that
improved RV function following pulmonary vasodilator
therapy occurs solely from improvements in longitudinal
contraction, suggesting that longitudinal shortening may
represent the afterload-responsive element of RV func-
tional recovery [38]. Finally, we do not estimate a possible
contribution of impaired diastolic reserve in the cardio-
vascular adaptation to the stress maneuver.
Conclusions
Pulmonary vascular reserve and RV systolic reserve are
impaired in PAH patients. The PA wall remodeling, pul-
monary buffering function and RV contractility appeared
as the main factors of the cardiovascular reserve dysfunc-
tion in PAH patients. The lower recruitable cardiovascular
reserve is significantly related to a worse hemodynamic
response to DST and it could be associated with a poor
clinical outcome. Further study is needed to elucidate
whether cardiovascular reserve dysfunction adds inde-
pendent prognostic information in a multivariate analysis.
In addition, further studies needs to assess whether im-
provement of cardiovascular reserve could be a thera-
peutic target in patients with established pulmonary
hypertension.
Abbreviations
CO: Cardiac output; DST: Dobutamine stress test with simultaneous 30°
Trendelenburg; EM: Elastic modulus; IVA: Myocardial acceleration during
isovolumic contraction; IVUS: Intravascular ultrasound; IVUSp: IVUS pulsatility;
mPAP: Mean pulmonary arterial pressure; PA: Pulmonary artery;
PAH: Pulmonary arterial hypertension; PC: Pulmonary capacitance;
pPAP: Pulse PAP; PVR: Pulmonary vascular resistance; RV: Right ventricle;Sm: Myocardial peak velocity during ejection phase; TAPSE: Tricuspid annular
plane systolic excursion; TPR: Total pulmonary resistance.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ED and JCG conceived of the study, participated in its design, conducted the
study, analyze the data, and wrote the manuscript. RA participated in the
design of the study, conducted the study and helped write the manuscript.
CA and NB conducted the study and analyze the data. MLM conceived of
the study and participated in its design. AR conceived of the study,
participated in its design, and wrote the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
Juan C Grignola is supported by CSIC (Cientific Research Sectorial Board) and
is a member (Researcher Level I) of ANII (National Agency of Research and
Innovation).
This study was presented in part in the 5th World Symposium of Pulmonary
Hypertension Niza, France, March 2013.
Author details
1Area del Cor, Hospital Universitari Vall d’Hebron, Barcelona, Spain.
2Physiology Department, School of Medicine, Universitat Autonoma,
Barcelona, Spain. 3Pathophysiology Department, School of Medicine, Hospital
de Clínicas, Universidad de la República, Avda Italia 2870, PC 11600
Montevideo, Uruguay. 4Department of Cardiology, Hospital de la Princesa,
Madrid, Spain. 5Department of Neumology, Hospital Vall d’Hebron, Barcelona,
Spain.
Received: 2 January 2014 Accepted: 4 April 2014
Published: 24 April 2014
References
1. Londsdorfer-Wolf E, Richard R, Doutrewleau S: Pulmonary hemodynamics
during strenuous intermittent exercise in healthy subjects. Med Sci Sports
Exerc 2003, 35:1866–1874.
2. Kovacs G, Berghold A, Scheidel S, Olschewski H: Pulmonary arterial
pressure during rest and exercise in healthy subjects: a systematic
review. Eur Respir J 2009, 34:888–894.
3. Reeves JT, Linehan JH, Stenmark KR: Distensibility of the normal
human lung circulation during exercise. Am J Lung Cell Mol Physiol
2005, 288:L419–L425.
4. Sun X-G, Hansen JE, Oudiz RJ, Wasserman K: Exercise pathophysiology
in patients with primary pulmonary hypertension. Circulation 2001,
104:429–435.
5. Arena R, Guazzi M, Myers J, Grinen D, Forman DE, Lavie CJ: Cardiopulmonary
exercise testing in the assessment of pulmonary hypertension. Expert Rev
Resp Med 2011, 5:281–293.
6. Holverda S, Gan CT-J, Marcus JT, Postmus PE, Boonstra A, Vonk-Noordegraaf
A: Impaired stroke volume response to exercise in pulmonary arterial
hypertension. J Am Coll Cardiol 2006, 47:1732–1733.
7. Laskey WK, Ferrari VA, Palevsky HI, Kussmaul WG: Pulmonary artery
hemodynamics in primary pulmonary hypertension. J Am Coll Cardiol
1993, 21:406–412.
8. Provencher S, Hervé P, Sitbon O, Humbert M, Simmoneau G, Chemla D:
Changes in exercise hemodynamics during treatment in pulmonary
arterial hypertension. Eur Respir J 2008, 32:393–398.
9. Lau EMT, Iyer N, Ilsar R, Bailey BP, Adams MR, Celermajer DS: Abnormal
pulmonary artery stiffness in pulmonary arterial hypertension: in vivo
study with intravascular ultrasound. PLoS One 2012, 7(3):e33331.
10. Roberts JD, Forfia PR: Diagnosis and assessment of pulmonary vascular
disease by Doppler echocardiography. Pulm Circ 2011, 1:160–181.
11. Blumberg FC, Arzt M, Lange T, Schroll S, Pfeifer M, Wensel R: Impact of
right ventricular reserve on exercise capacity and survival in patients
with pulmonary hypertension. Eur J Heart Fail 2013, 15:771–775.
12. Badesch D, Champion HC, Gomez Sanchez MA, Hoeper MM, Loyd JE,
Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A:
Diagnosis and assessment of pulmonary arterial hypertension. J Am
Coll Cardiol 2009, 54:S55–S66.
Domingo et al. BMC Pulmonary Medicine 2014, 14:69 Page 10 of 10
http://www.biomedcentral.com/1471-2466/14/6913. Hoeper M, Maier R, Tongers J, Niedermeyer J, Hohlfeld J, Hamm M, Fabel H:
Determination of cardiac output by the Fick method, termodilution and
acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care
Med 1999, 160:535–541.
14. Laurent S, Cockroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D,
Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H: Expert Consensus
Document on Arterial Stiffness : methodological issues and clinical
applications. Eur Heart J 2006, 27:2588–2602.
15. Saggar R, Lewis GD, Systrom DM, Champion HC, Naeije R, Saggar R:
Pulmonary vascular responses to exercise: a haemodynamic observation.
Eur Respir J 2012, 39:231–234.
16. Rodés-Cabau J, Domingo E, Roman A, Majó J, Lara B, Padilla F, Anívarro I,
Angel J, Tardif JC, Soler-Soler J: Intravascular ultrasound of the elastic
pulmonary arteries: a new approach for the evaluation of primary
pulmonary hypertension. Heart 2003, 89:311–315.
17. Grignola JC, Domingo E, Bravo C, Aguilar R, López Messeguer M, Vázquez M,
Roman A: Local pulmonary artery stiffness indexes are correlated with
steady and pulsatile components of right ventricular afterload in
pulmonary arterial hypertension [abstract]. J Am Coll Cardiol 2010, 55:A367.
18. Grignola JC, Domingo E, Aguilar R, Vázquez M, López-Messeguer M, Bravo C,
Roman A: Acute absolute vasodilatation is associated with a lower
vascular wall stiffness in pulmonary arterial hypertension. Int J Cardiol
2013, 164:227–231.
19. Rudski LG, Lai WW, Afilalo J, Hua L, Handshumacher MD, Chandrasekaran K,
Solomon SD, Louie EK, Schiller NB: Guidelines for the echocardiographic
assessment of right heart in adults: a report from the American Society
of Echocardiography endorsed by the European Association of
Echocardiography, a registered branch of the European Society of
Cardiology, and the Canadian Society of Echocardiography. J Am Soc
Echocardiogr 2010, 23:685–713.
20. Vogel M, Schmidt MR, Kristiansen SB, Cheung M, White PA, Sorensen K,
Redington AN: Validation of myocardial acceleration during isovolumic
contraction as a novel noninvasive index of right ventricular
contractility: comparison with ventricular pressure-volume relations in
an animal model. Circulation 2002, 105:1693–1699.
21. Haddad F, Vrtovec B, Ashley EA, Deschamps A, Haddad H, Denault AY:
The concept of ventricular reserve in heart failure and pulmonary
hypertension: an old metric that brings us one step closer in our quest
for prediction. Curr Opin Cardiol 2011, 26:123–131.
22. Pagnamenta A, Fesler P, Vandinivit A, Brimipoulle S, Naeije R: Pulmonary
vascular effects of dobutamine in experimental pulmonary hypertension.
Crit Care Med 2003, 31:1140–1146.
23. Vizza CD, Rocca GD, Di Roma A, Iacobino C, Pierconti F, Venuta F, Rendina
E, Schmid G, Pietropaoli P, Fedele F: Acute hemodynamic effects of
inhaled NO, dobutamine and a combination of the two in patients with
mild to moderate pulmonary hypertension. Crit Care 2011, 5:355–361.
24. Bossone E, Naeije R: Exercise induced pulmonary hypertension. Heart Failure
Clin 2012, 8:485–495.
25. Kovacs G, Olschewski A, Berghold A, Olschewski H: Pulmonary vascular
resistances during exercise in normal subjects: a systematic review.
Eur Respir J 2012, 39:319–328.
26. Merkus D, de Beer VJ, Houweling B, Duncker DJ: Control of pulmonary
vascular tone during exercise in health and pulmonary hypertension.
Pharmacol Ther 2008, 119:242–263.
27. Bia D, Barra JG, Grignola JC, Ginés F, Armentano R: Pulmonary artery
smooth muscle activation attenuates arterial dysfunction during acute
pulmonary hypertension. J Appl Physiol 2005, 98:605–613.
28. Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G:
Heart rate responses during 6-minute walk test in pulmonary arterial
hypertension. Eur Respir J 2006, 27:114–120.
29. Dimopoulos S, Anastasiou-Nana M, Katsaros F, Papazachou O, Tzanis G,
Gerovasili V, Pozios H, Roussos C, Nanas J, Nanas S: Impairment of
autonomic nervous system activity in patients with pulmonary arterial
hypertension: a case control study. J Card Fail 2009, 15:882–889.
30. Wensel R, Opitz C, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R,
Hummel M, Hetzer R, Ewert R: Assessment of survival in patients with
primary pulmonary hypertension-importance of cardiopulmonary
exercise testing. Circulation 2002, 106:319–324.
31. Kubo K, Ge RL, Koizumi T, Fujimoto K, Yamanda T, Haniuda M, Honda T:
Pulmonary artery remodeling modifies pulmonary hypertension during
exercise in severe emphysema. Resp Physiol 2000, 120:71–79.32. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemmes AR, Borlaug BA,
Chamera E, Corretti MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM:
Tricuspid annular displacement predicts survival in pulmonary hypertension.
Am J Respir Crit Care Med 2006, 174:1034–1041.
33. Hacobian M, Cohen MC, Atherton D, Wirth JA: Right ventricular exercise
echocardiographic predictors of worsened clinical status in patients with
pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2011,
183:A4996.
34. Giusca S, Dambrauskaite V, Scheurwegs C, D’hooge J, Claus P, Herbots L,
Magro M, Rademakers F, Meyns B, Delcroix M, Voigt JU: Deformation
imaging describes right ventricular function better than longitudinal
displacement of the tricuspid ring. Heart 2010, 96:281–288.
35. Gómez A, Bialostozky D, Zajarias A, Santos E, Palomar A, Martínez ML,
Sandoval J: Right ventricular ischemia in patients with primary
pulmonary hypertension. J Am Coll Cardiol 2001, 38:1137–1142.
36. Wong YY, Raijmakers PG, Knaapen P, Lubberink M, Ruiter G, Marcus JT, Boonstra
A, Lammertsma AA, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf
A: Supine-exercise-induced oxygen supply to the right myocardium
is attenuated in patients with severe idiopathic pulmonary arterial
hypertension. Heart 2011, 97:2069–2076.
37. Derrick GP, Narang I, White PA, Kelleher A, Bush A, Penny DJ, Redington AN:
Failure of stroke volume during exercise and dobutamine stress is
unrelated to load-independent indexes of right ventricular performance
after the Mustard operation. Circulation 2000, 102(SupplIII):154–159.
38. Brown SB, Raina A, Katz D, Szerlip M, Wiegers SE, Forfia PR: Longitudinal
shortening accounts for the majority of right ventricular contraction and
improves after pulmonary vasodilator therapy in normal subjects and
patients with pulmonary arterial hypertension. Chest 2011, 140:27–33.
doi:10.1186/1471-2466-14-69
Cite this article as: Domingo et al.: Impairment of pulmonary vascular
reserve and right ventricular systolic reserve in pulmonary arterial
hypertension. BMC Pulmonary Medicine 2014 14:69.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
